105Rh[1,5,9,13-tetrathiacyclohexadecane-3,11-diol] is a promising drug precursor for targeted radiotherapy. Nevertheless, the
axial position of chloride ions in the complex structure and their weak binding to rhodium centre, due to HSAB concept, make
such a complex subject to modifying action of certain sulphuric ligands, like human plasma thiol antioxidants: glutathione
and cysteine. Experiments were performed with both radioactive 105Rh and inactive rhodium. The complexation of rhodium with 1,5,9,13-tetrathiacyclohexadecane-3,11-diol (16S4diol) resulted in three distinct peaks seen on UV, radiometric and MS chromatograms. The substitution of chlorides was noted
in over 80% of 105[Rh(16S4diol)Cl2]+ units after incubation with glutathione, and less than 10% of complex units after incubation with cysteine (24 h, 37 °C).
Reaction of 105[Rh(16S4diol)Cl2]+ with 1,8-octandithiol and 1,9-nonandithiol resulted in disappearance of the complex peak and occurrence of two new peaks.
Product of RhCl3 and 16S4diol reaction is a mixture of three distinct forms having different number of chlorine atoms. Our in vitro experiments suggest
that the substitution of axial chlorides with glutathione and cysteine might also occur in vivo in human plasma. Glutathione
shows higher reactivity than cysteine in replacement reaction. Axial positions in precursor might be effectively blocked by
1,8-octandithiol and 1,9-nonandithiol.